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Objectives: Cancer-related pain in children is prevalent and undermanaged. Mobile health 
(mHealth) applications provide a promising avenue to address the gap in pain management in 
children with cancer. Pain Buddy is a multi-component mHealth application developed to 
manage cancer-related pain in children. The goal of this paper is to present preliminary efficacy 
data of the impact of Pain Buddy on children’s pain severity and frequency. Methods: In a 
randomized controlled trial over 60 days, children (N=48) reported daily pain on a tablet while 
receiving usual care. Those in the intervention group (N=20) received remote symptom 
monitoring and skills training for pain management. Children in the attention control group 
(N=28) only reported on their pain. Results: Both groups experienced significant reductions in 
average daily pain over the study period (B=-0.10, z=-3.40, p=.001), with no group differences 
evident (z=-0.83, p=.40). However, the intervention group reported significantly fewer instances 
of moderate to severe pain compared to the control group, t(4125)=2.67, p=0.007. In addition, 
the intervention group reported no instances of moderate to severe pain toward the end of the 
study period. Conclusion: Pain Buddy is an innovative and interactive mHealth application that 
aims to improve pain and symptom management among children with cancer. The findings from 
this pilot study suggest that Pain Buddy may aid in the reduction of pain severity in children 
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INTRODUCTION 
Over 10,000 children in the United States are diagnosed with cancer every year1 and 
significant symptoms, such as recurrent pain, often accompany its treatment2.  Furthermore, 
children are in particular need of easily implementable interventions because the majority of 
pediatric pain management responsibility has shifted from medical settings to home 
environments3. Because mobile health (mHealth) applications have great potential to improve 
pediatric pain management4, our group developed Pain Buddy as an intervention designed to 
reduce pain during cancer treatment by facilitating patient-provider symptom communication, 
providing children training in cognitive and behavioral pain management strategies, and 
delivering these techniques in an effective and engaging manner5. Users of the present version of 
Pain Buddy are asked to report on their daily pain and symptoms via a computer tablet and that 
information is provided in real time to clinicians in order to promptly address any symptoms that 
warrant intervention. Thus, Pain Buddy bridges the research-to-practice gap in the current state 
of care for children undergoing cancer treatment by providing a medium by which pain and 
symptoms can be better managed in the home setting.  
Retrospective pain reporting can be inaccurate and thus hinder the effectiveness of pain 
management strategies in the medical setting6; however, tracking symptoms in real time through 
e-diaries is a successful strategy that augments patient-provider communication5–7. Accordingly, 
Pain Buddy collects twice daily e-diary symptom reports (e.g., pain, nausea, fatigue) and 
provides a remote symptom monitoring communication system that allows healthcare providers 
to track patterns of symptoms and provide timely intervention to patients in need. The data from 
Pain Buddy are routed through a server and can be accessed by the appropriate healthcare 
provider through an administrative portal via the Pain Buddy web app. When a child reports 
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symptoms that warrant intervention (determined based upon an algorithm developed in 
collaboration with the treatment team), the specific symptoms reported are sent immediately to 
the appropriate provider via text or email message. In addition, in order to address the research-
to-practice gap that has limited the translation of evidence-based strategies into the home 
setting8, Pain Buddy incorporates coping skills shown to be effective in the management of pain, 
such as diaphragmatic breathing9, progressive muscle relaxation10, guided imagery11, 
distraction12, and mindfulness. Trainings for these skills can be accessed at any time and are also 
linked to children’s symptom reports such that based upon symptom severity, duration, 
frequency, and/or distress, children are directed to the skills component of Pain Buddy. To 
overcome problems with lack of engagement that have limited the success of similar 
applications13, Pain Buddy includes features such as a virtual store in which children can use 
coins accumulated during use of the skills training exercises to customize their personalized 
avatar and purchase additional background themes.  
There are several other mHealth interventions targeting pediatric pain such as WebMap14 
and Pain Squad+15 that have been developed and evaluated. Pain Squad+ is an innovative app 
that addresses pediatric pain and allows for real-time communication with healthcare providers. 
WebMap is an online platform that provides evidence-based pain management skills training for 
pediatric pain. However, Pain Buddy is unique because it combines all of these elements and 
focuses specifically on cancer-related pain and symptoms, contains real-time communication 
features with healthcare providers, and has extensive pain management skills training instruction, 
including strategies such as mindfulness, imagery, and distraction that can be practiced over time 
to develop competency. We have previously reported on the development and 
usability/feasibility testing of Pain Buddy5. The purpose of this paper is to present preliminary 
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findings from a pilot study examining the efficacy of Pain Buddy for reducing reports of average 
pain and instances of moderate to severe pain using a randomized controlled trial over a period 
of 60 days.  We hypothesized that individuals in the intervention group would report greater 
reductions of average daily pain and fewer instances of moderate to severe pain than those in the 
control group. 
METHOD 
Design & Participants  
A prospective, observational cohort study was conducted to investigate the efficacy of 
Pain Buddy. This trial was approved by the Institutional Review Boards at Children’s Hospital of 
Orange County (CHOC Children’s) and the University of California, Irvine and registered with 
ClinicalTrials.gov (NCT03384134). Figure 1 presents a CONSORT flow diagram of participant 
recruitment. Children were eligible to participate if they were between the ages of 8-18 years, 
currently undergoing cancer treatment at a major children’s hospital, have home internet access, 
and were able to speak, read and write in English. Participants were excluded if they had a 
cognitive or developmental delay that would prevent them from being able to use Pain Buddy. A 
total of 447 children were assessed for eligibility and 48 children completed the study (see Table 
1 for demographics). Our sample size was determined based on published recommendations for 
pilot studies16 and expected effect sizes from similar studies15. The majority of participants 
(71%) were diagnosed with Acute Lymphoblastic Leukemia. 
Procedures 
Parents and children were approached in outpatient clinics, assessed for eligibility and 
consented to participate. Parent consent forms and questionnaires were available in English or 
Spanish. After undergoing the consent and training processes, all children completed baseline 
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assessments and were randomly assigned to the intervention (n = 20) or attention control group 
(n = 28). Randomization was stratified by age (8-10, 11-14, and 15-18) and then time since 
diagnosis (<6months, 6-12 months, +1 year) by eight project researchers using an online 
randomization generator. Participants in both conditions were provided with the Pain Buddy 
application on a study-specific Android tablet and instructed to complete twice daily symptom 
diaries (once in the morning, once in the evening) in English using the Memorial Symptom 
Assessment Scale (MSAS)17 and Adolescent Pediatric Pain Tool (APPT)18. The MSAS evaluated 
the frequency, severity, and distress related to particular symptoms since the time of their last 
diary entry. If pain was endorsed on the MSAS, children filled out the APPT to report their pain 
intensity. Both groups were instructed to complete these surveys each day, however, only the 
intervention group had access to the skills training and remote symptom monitoring components.  
For children in the intervention group, an algorithm was used to determine if their pain 
ratings met a certain threshold that warranted intervention, which included notification of a nurse 
practitioner (NP) via the remote symptom monitoring component. The algorithm triggered 
notification if a pain rating was over 7.5, or if there was a combination of reporting significant 
frequency, severity, and distress of the pain (see5 for full description of intervention algorithm). 
Symptom alerts were immediately sent to the NP, who is a member of the oncology treatment 
team and was the only NP involved in this study.  The alerts were treated as a “sick call,” 
wherein a family contacts the clinic when a child is experiencing new or worsening symptoms.  
The response to the pain alert was not dictated by the study protocol.  That is, the NP handled the 
pain alert as she would if a “sick call” had been made.  Thus, Pain Buddy does not necessarily 
introduce a change in medical treatment but allows for increased and more immediate awareness 
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of pain data that allowed for more prompt intervention. Children used the Pain Buddy program 
for 60 days in addition to receiving usual care.  
Measures 
Adolescent Pediatric Pain Tool (APPT) 
The APPT is a multidimensional, valid and reliable pain instrument. If pain was endorsed 
on the MSAS during a daily diary entry, then children were presented with a body outline via the 
APPT and asked to select the areas where they felt pain since their last diary entry. Following 
this step, self-reported pain intensity was reported by the child on a visual analog scale from 0 -
100 in which the child was asked, “How much pain did you have, on average, since your last 
diary entry”. This type of visual scale has been validated for children 8-18 years of age (Stinson, 
Kavanagh, Yamada, Gill, & Stevens, 2006). Our primary outcome of average daily pain was 
derived from the APPT. The secondary outcome considered was instances of moderate to severe 
pain, defined as pain episodes greater than or equal to 50. 
Memorial Symptom Assessment Scale (MSAS)  
This instrument evaluated the presence, frequency and effect of particular symptoms 
since the time of the last diary entry. Children were presented with a symptom description and 
asked to select “yes” or “no” if they have experienced it. If the child responded “yes”, then 
follow-up questions asked the child to describe the frequency of its occurrence, the severity of its 
impact, and the distress it caused. Children also had the option to list additional symptoms and 
associated effects. This scale has two different versions that are designed for specific age groups. 
The MSAS 7-12 assesses 8 symptoms and is designed for children 7-12 years old (Collins et al., 
2000). The MSAS 10-18 assesses 30 symptoms and is designed for children 10-18 years old. For 
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this paper, the MSAS was simply used as a tool to determine if it was necessary for the child to 
complete the APPT during that particular diary entry. 
Participant Characteristics 
Parents reported via a demographic survey on child age, sex, race/ethnicity, primary 
language spoken at home, and family income. Diagnosis and time since diagnosis were 
abstracted from the medical record. 
Approach to Data Analysis 
Preliminary analyses were conducted to examine group differences on sociodemographic 
variables of interest. Independent samples t-tests were used to compare differences in continuous 
variables (age, time since diagnosis), a Mann-Whitney U test was used to compare differences in 
skewed continuous variables (income), and chi-squared analyses were used to compare 
differences in categorical variables (sex, race/ethnicity, primary language spoken at home, 
diagnosis). Pain severity from the two e-diary pain reports from each day were averaged together 
into an average daily pain severity score. Linear growth curve modeling was used to investigate 
the trajectory of pain reports over the course of the study for both groups. Maximum likelihood 
estimation was used to handle missing data for growth curve modeling analyses and listwise 
deletion was used for all other analyses. Average daily pain scores were checked for skewness 
and kurtosis, with results showing left-skewness. Therefore, a Mann-Whitney-Wilcoxon sum 
rank test was used to test for differences between the intervention and control groups on average 
daily pain severity. Frequency of moderate to severe pain episodes were compared between 
groups using an independent samples t-test.  
RESULTS  
 
Preliminary efficacy of Pain Buddy 9 
Across both groups, children completed 61.2% of the daily diary entries. Within the Pain 
Buddy group, on average children used 7 skills trainings for a total of 15 minutes over the course 
of the study. Unconditional linear growth curve analyses indicated that reports of average daily 
pain significantly decreased over the course of the study, B=-0.10, z=-3.40, p=0.001, 95% CI [-
.1594, -.0429]. Mann-Whitney-Wilcoxon tests indicated that the reports of average daily pain 
over the course of the study for the Pain Buddy group were not significantly different than the 
reports of average daily pain for the attention control group, z=-0.83, p=0.40 (see Figure 2). 
However, children in the intervention group reported significantly fewer instances of moderate to 
severe pain compared to the control group, t(2145)=2.67, p=0.008, 95% CI [.0036, .0235]. 
Specifically, children in the Pain Buddy condition experienced 6 moderate to severe pain 
episodes compared to 24 moderate to severe pain episodes experienced by the attention control 
group. Furthermore, children in the intervention condition only reported moderate to severe pain 
episodes during the first 18 days of the study, whereas the control group reported these episodes 
through Day 53.   
DISCUSSION 
 Under the conditions of this study, we found that children undergoing treatment for 
cancer experienced a decrease in pain severity over time, which did not differ between the 
intervention and attention control groups. The overall decrease in pain severity for both groups 
may have simply been due to the time elapsed since diagnosis/treatment. Findings also showed 
that children in the active intervention condition of Pain Buddy, that is, children who had access 
to remote symptom monitoring and cognitive and behavioral skills training for pain management 
evidenced significantly fewer moderate to severe pain episodes over the course of the 60-day 
study compared to children who only reported on their symptoms daily. Furthermore, children in 
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the intervention condition did not report any moderate to severe pain episodes in the latter parts 
of the study.  
The modest, but promising, effects of Pain Buddy on pain during cancer treatment are 
comparable to similar mHealth pediatric pain intervention studies19. Similar to the effects of 
WebMap15, which also provides evidence-based pain management skills training for pediatric 
pain, both groups in the present study demonstrated pain reductions over the course of the study 
but there were no significant differences in the change of pain intensity between the attention 
control and intervention groups. However, our trial uniquely demonstrated that children in the 
intervention group reported fewer instances of moderate to severe pain over the course of the 
study. This implies that Pain Buddy may be particularly advantageous for assisting children who 
have significantly elevated levels of pain and also has implications for outcomes of pain 
intervention studies. Furthermore, similar interventions with mobile pain assessment and real-
time pain management support, such as Pain Squad+, have demonstrated comparable adherence 
rates for pain assessment completion and have been shown to reduce pain for children14, however, 
efficacy has not yet been demonstrated in a randomized controlled trial. Thus, this pilot study of 
Pain Buddy offers several distinctive contributions to the pediatric mHealth literature. 
More specifically, when placed in the context of existing literature, our findings suggest 
that it is likely that pain experienced by children during cancer treatment decreases over time 
perhaps regardless of the various interventions examined.  This was demonstrated both in a prior 
examination of Pain Squad+ as well as in the findings of the present study; that is, users of the 
previous interventions experienced significant reductions in pain severity over time.  However, 
the prior evaluation of Pain Squad+ did not contain a comparison group and was an examination 
of pain over time in one group of children using the intervention.  Conversely, the present 
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investigation evaluated Pain Buddy using an RCT study design, which allowed for a comparison 
of the intervention to an attention control group.  This provided an opportunity to discern  
whether the intervention itself had an impact on pain severity or whether pain severity simply 
decreases over time throughout cancer treatment and/or whether monitoring pain perhaps 
contributes to reductions in pain severity over time.  By comparing pain monitoring (our 
attention control group) with monitoring, skills training, and remote symptom assessment (our 
intervention group), we were able to discern potential active treatment components.  In fact, 
whereas we did not see significant group differences in pain severity over time, suggesting that 
either the act of monitoring influences pain severity or severity decreases as an effect of time, we 
did see significant impacts of the intervention on the frequency of painful episodes over time.  
Thus, our between-subjects comparison of the intervention and attention control groups advances 
our understanding of the impact of mHealth interventions for pain by suggesting that pain 
severity may not be the most important outcome of interest and that these interventions may be 
particularly efficacious for reducing frequency of pain episodes over time rather than average 
pain severity over time. Accordingly, this study informs important outcomes when assessing the 
impact of mHealth interventions for cancer-related pain by suggesting that focusing exclusively 
on pain severity may not be sufficient and perhaps broadening the focus to assess pain episodes 
as well is more indicative of the targeted impact of interventions that include both pain 
monitoring and skills training. Moreover, these findings indicate that Pain Buddy is a promising 
mHealth intervention for pain management in children undergoing cancer treatment. 
Limitations & Future Directions 
 Although it was expected that the intervention group would experience significantly 
greater reductions in pain over the course of the 60-day study compared to the attention control 
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group, this was not the case. It is likely that because pain reports were skewed (the median was 0 
for both groups), there may have been a floor effect that limited the potential effectiveness of the 
intervention. Thus, it may be important to focus on children who are actively experiencing pain 
with such an intervention. Furthermore, engagement with the skills training was lower than 
expected in this trial and may have hindered the effectiveness of the intervention.  Efforts to 
increase engagement with mHealth interventions is vital. Finally, because this was a pilot study, 
the participant sample was small, which may have limited the findings.   
Based upon this initial pilot, we are currently conducting a large-scale, multi-site trial of 
Pain Buddy with the aim of gathering effectiveness data. These early results guided several 
modifications to the Pain Buddy program as well as our procedures and patient population in 
order to increase engagement and be able to focus on a broader range of outcomes. More 
specifically, we gamified Pain Buddy to increase engagement, are recruiting only children who 
have experienced clinically significant pain in the month prior to study enrollment, and recruiting 
children who are within the first 16 weeks of a cancer diagnosis, a period when pain may be at its 
highest20. Once we complete our effectiveness trial, our goals are to examine ways in which Pain 
Buddy may need to be tailored to be relevant to specific populations (e.g., a wider age range, 
different cultural backgrounds) as well as to partner with hospitals in order to make Pain Buddy 
available to children undergoing cancer treatment. Pain Buddy data are clinically relevant, are 
designed to improve the clinical care of children undergoing cancer treatment, and could 
ultimately become part of a child’s medical record.  
Our goal is to bridge the gap in knowledge translation in the management of pain in 
children undergoing cancer treatment and demonstrate that the use of mHealth programs such as 
Pain Buddy will provide an avenue in which to accomplish this aim. Continued stakeholder 
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involvement in the development of Pain Buddy, large-scale efficacy testing, and dissemination to 
those in need will ensure that Pain Buddy continues to have a positive impact on pediatric pain 
management. 
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FIGURE 1. Participant flow diagram through the Pain Buddy pilot study 
 
FIGURE 2. Average daily pain significantly declined over the course of the study for both 
groups. However, there were no significant differences in pain trajectory between the control and 
Pain Buddy groups. Error bars represent 95% confidence intervals. 
 
 
Assessed for eligibility (n=447) 
Excluded (n=394) 
 Not meeting inclusion criteria (n=282) 
   Does not have qualifying diagnosis (n=10) 
   Limited English (n=6) 
   Outside age range (n=194) 
   No longer on treatment (n=35) 
   Receives other special needs services (n=32) 
   Does not have internet at home (n= 5) 
 Declined to participate (n=42) 
   Not interested (n=17) 
   Time (n=11) 
   Health (n=5) 
   Other/Unknown (n=9) 
 Could not approach (n=23) 
 Other (passed away) (n=47) 
 
Analysed  (n=20) 
 
Lost to follow-up (n=0) 
Discontinued intervention (n=2) 
 Did not complete daily diary entries 
 
Allocated to intervention (n=22) 
 
Lost to follow-up (n=0) 
Discontinued intervention (n=3) 
 Did not complete daily diary entries 
 
Allocated to attention control (n=31) 
 









TABLE 1 Demographic characteristics did not differ by treatment condition. 
Note: Some demographic data was missing, however, percentages reported reflect the proportion 
of the available data (i.e. valid percent). Abbreviations: CNS = Central Nervous System 
a n (%) 
b M (SD) 




Intervention, n = 20  
 
Control, n = 28 
 
t/χ2/z p 
Sex a   1.34 0.25 
 Male 12 (63.2) 22 (78.6)   
 Female 7 (36.8) 6 (21.4)   
Race/ Ethnicity a   7.87 0.34 
 Hispanic  12 (60.0) 21 (77.8)   
 White 5 (25.0) 2 (7.4)   
 Asian 3 (15.0) 2 (7.4)   
 Other 0 (0.0) 2 (7.4)   
Primary Language at Home a   1.79 0.78 
 English 10 (52.6) 16 (57.1)   
 Spanish 8 (42.1) 9 (32.1)   
 Other 1 (5.3) 3 (10.7)   
Diagnosis a   3.77 0.44 
 Leukemias 17 (85.0) 17 (60.7)   
 Lymphomas 1 (5.0) 3 (10.7)   
 Sarcomas 1 (5.0) 3 (10.7)   
 CNS Tumors 1 (5.0) 3 (10.7)   
 Other 0 (0.0) 2 (7.1)   
Months Since Diagnosis b  19.50 (26.35) 19.39 (20.12) 0.02 0.99 
Age b 12.25 (3.58) 11.86 (3.44) 0.38 0.70 
Median Family Annual Income c 29,000.00  
(14,400.00 – 
45,000.00) 
37,500.00  
(20,100.00 – 
78,750.00) 
-1.11 0.27 
